Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.43M | Buy |
94,169
+1,340
| +1% | +$76.9K | 0.81% | 42 |
|
|
2026
Q1 | $5.63M | Sell |
92,829
-7,684
| -8% | -$448K | 0.96% | 38 |
|
|
2025
Q4 | $5.42M | Sell |
100,513
-11,157
| -10% | -$537K | 0.89% | 40 |
|
|
2025
Q3 | $5.04M | Buy |
111,670
+9,815
| +10% | +$458K | 0.79% | 39 |
|
|
2025
Q2 | $4.71M | Sell |
101,855
-123,989
| -55% | -$6.09M | 0.8% | 40 |
|
|
2025
Q1 | $13.8M | Sell |
225,844
-10,625
| -4% | -$619K | 2.39% | 15 |
|
|
2024
Q4 | $13.4M | Sell |
236,469
-1,910
| -0.8% | -$107K | 2.4% | 16 |
|
|
2024
Q3 | $12.3M | Buy |
238,379
+31,103
| +15% | +$1.46M | 2.19% | 17 |
|
|
2024
Q2 | $8.61M | Buy |
207,276
+16,565
| +9% | +$741K | 1.72% | 23 |
|
|
2024
Q1 | $10.3M | Buy |
190,711
+7,633
| +4% | +$389K | 1.97% | 22 |
|
|
2023
Q4 | $9.39M | Sell |
183,078
-32,528
| -15% | -$1.71M | 1.85% | 25 |
|
|
2023
Q3 | $12.5M | Sell |
215,606
-1,952
| -0.9% | -$120K | 2.83% | 11 |
|
|
2023
Q2 | $13.9M | Buy |
217,558
+23,159
| +12% | +$1.55M | 2.98% | 9 |
|
|
2023
Q1 | $13.5M | Buy |
194,399
+36,202
| +23% | +$2.55M | 3.09% | 10 |
|
|
2022
Q4 | $11.4M | Sell |
158,197
-5,315
| -3% | -$401K | 2.8% | 12 |
|
|
2022
Q3 | $11.6M | Sell |
163,512
-3,443
| -2% | -$250K | 3.28% | 9 |
|
|
2022
Q2 | $12.9M | Sell |
166,955
-24,752
| -13% | -$1.89M | 3.18% | 10 |
|
|
2022
Q1 | $14M | Sell |
191,707
-23,364
| -11% | -$1.57M | 2.99% | 11 |
|
|
2021
Q4 | $13.4M | Sell |
215,071
-28,554
| -12% | -$1.67M | 2.78% | 14 |
|
|
2021
Q3 | $14.4M | Sell |
243,625
-22,732
| -9% | -$1.5M | 3.15% | 11 |
|
|
2021
Q2 | $17.8M | Sell |
266,357
-12,196
| -4% | -$795K | 3.78% | 4 |
|
|
2021
Q1 | $17.6M | Buy |
278,553
+73,665
| +36% | +$4.58M | 3.93% | 5 |
|
|
2020
Q4 | $12.7M | Buy |
204,888
+478
| +0.2% | +$29.4K | 3.47% | 9 |
|
|
2020
Q3 | $12.3M | Buy |
204,410
+3,478
| +2% | +$209K | 3.87% | 7 |
|
|
2020
Q2 | $11.8M | Buy |
200,932
+27,612
| +16% | +$1.65M | 3.94% | 7 |
|
|
2020
Q1 | $9.66M | Buy |
+173,320
| New | +$10.6M | 3.54% | 7 |
|
|
2019
Q1 | – | Sell |
-201,655
| Closed | -$10.5M | – | 84 |
|
|
2018
Q4 | $10.5M | Buy |
201,655
+8,481
| +4% | +$456K | 3.25% | 8 |
|
|
2018
Q3 | $12M | Buy |
193,174
+6,805
| +4% | +$404K | 3.06% | 8 |
|
|
2018
Q2 | $10.3M | Buy |
186,369
+149,187
| +401% | +$8.06M | 2.77% | 10 |
|
|
2018
Q1 | $2.35M | Buy |
+37,182
| New | +$2.39M | 0.63% | 45 |
|
Other funds holding BMY
Capital Management's BMY Position: Q2 2026 in Review
Capital Management increased its Bristol-Myers Squibb (BMY) stake by 1.4% in Q2 2026, buying an estimated $76.9K and bringing the position to 94,169 shares worth $5.43M. The position accounts for 0.81% of the portfolio, ranked #42.
Capital Management first reported a position in BMY in Q1 2018 and has held it in 30 quarters since. The position peaked at $17.8M in Q2 2021. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Capital Management held 94,169 shares of Bristol-Myers Squibb worth $5.43M as of Q2 2026.
- Capital Management bought 1,340 Bristol-Myers Squibb shares in Q2 2026, an estimated $76.9K.
- Bristol-Myers Squibb made up 0.81% of Capital Management's portfolio in Q2 2026, its #42 holding.
- Capital Management first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 30 quarters since.
- Capital Management's Bristol-Myers Squibb position peaked at $17.8M in Q2 2021.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.